Pegasys and Copegus for Asian patients with treatment-naive hepatitis C genotypes 6, 7, 8, 9: a phase IV, randomized, open-labeled, multicenter trial comparing 24-week vs. 48-week therapy.

Trial Profile

Pegasys and Copegus for Asian patients with treatment-naive hepatitis C genotypes 6, 7, 8, 9: a phase IV, randomized, open-labeled, multicenter trial comparing 24-week vs. 48-week therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top